Zydus Lifesciences Ltd has announced an exclusive licensing and supply agreement with MSN Laboratories for the generic cancer treatment drug Cabozantinib tablets in the US market. The agreement grants MSN Laboratories the responsibility of manufacturing and supplying the generic version of CABOMETYX, with Zydus exclusively handling marketing, distribution, and sales. This partnership highlights Zydus’ dedication to providing affordable medications to patients. With a substantial market opportunity estimated at approximately USD 1,464 million, the move aims to enhance accessibility to vital cancer treatments.
Zydus Lifesciences Secures Licensing Deal for Cancer Drug Cabozantinib Tablets
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/05/18104205/1713767625-6711-ezgif.com-avif-to-jpg-converter.jpg)